726 related articles for article (PubMed ID: 27882374)
1. Cancer-associated venous thromboembolism: Burden, mechanisms, and management.
Ay C; Pabinger I; Cohen AT
Thromb Haemost; 2017 Jan; 117(2):219-230. PubMed ID: 27882374
[TBL] [Abstract][Full Text] [Related]
2. Management of cancer-associated venous thromboembolism - a case-based practical approach.
Voigtlaender M; Langer F
Vasa; 2018 Feb; 47(2):77-89. PubMed ID: 29325495
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
[TBL] [Abstract][Full Text] [Related]
4. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.
Hillis C; Crowther MA
Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149
[TBL] [Abstract][Full Text] [Related]
5. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients.
Song AB; Rosovsky RP; Connors JM; Al-Samkari H
Vasc Health Risk Manag; 2019; 15():175-186. PubMed ID: 31417269
[TBL] [Abstract][Full Text] [Related]
6. Treatment of thromboembolism in cancer patients.
Panova-Noeva M; Falanga A
Expert Opin Pharmacother; 2010 Aug; 11(12):2049-58. PubMed ID: 20642371
[TBL] [Abstract][Full Text] [Related]
7. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Khorana AA; Weitz JI
Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
9. Predicting anticoagulant-related bleeding in patients with venous thromboembolism: a clinically oriented review.
Klok FA; Kooiman J; Huisman MV; Konstantinides S; Lankeit M
Eur Respir J; 2015 Jan; 45(1):201-10. PubMed ID: 25102964
[TBL] [Abstract][Full Text] [Related]
10. VTE and anti-coagulation therapy in cancer patients.
Miyazaki Y; Sase K; Hasegawa K; Morimoto T
Eur Heart J Cardiovasc Pharmacother; 2019 Oct; 5(4):189-191. PubMed ID: 31378809
[No Abstract] [Full Text] [Related]
11. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E; Rocha E
Vasc Health Risk Manag; 2013; 9():207-28. PubMed ID: 23674896
[TBL] [Abstract][Full Text] [Related]
12. Treatment of venous thromboembolism.
Wells PS; Forgie MA; Rodger MA
JAMA; 2014 Feb; 311(7):717-28. PubMed ID: 24549552
[TBL] [Abstract][Full Text] [Related]
13. Management of idiopathic venous thromboembolism.
Cosmi B
Expert Rev Cardiovasc Ther; 2016 Dec; 14(12):1371-1384. PubMed ID: 27740860
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: an oral factor Xa inhibitor.
Thomas TF; Ganetsky V; Spinler SA
Clin Ther; 2013 Jan; 35(1):4-27. PubMed ID: 23328267
[TBL] [Abstract][Full Text] [Related]
15. The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism - still a challenging issue.
Elmi G; Di Pasquale G; Pesavento R
Vasa; 2017 Mar; 46(2):87-95. PubMed ID: 28102773
[TBL] [Abstract][Full Text] [Related]
16. Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism.
Beyer-Westendorf J; Ageno W
Thromb Haemost; 2015 Feb; 113(2):231-46. PubMed ID: 25319150
[TBL] [Abstract][Full Text] [Related]
17. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
[TBL] [Abstract][Full Text] [Related]
18. Management and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study.
Kahn SR; Springmann V; Schulman S; Martineau J; Stewart JA; Komari N; McLeod A; Strulovitch C; Blostein M; Faucher JP; Gamble G; Gordon W; Kagoma PK; Miron MJ; Laverdière D; Game M; Mills A
Thromb Haemost; 2012 Sep; 108(3):493-8. PubMed ID: 22782073
[TBL] [Abstract][Full Text] [Related]
19. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.
Bates SM; Rajasekhar A; Middeldorp S; McLintock C; Rodger MA; James AH; Vazquez SR; Greer IA; Riva JJ; Bhatt M; Schwab N; Barrett D; LaHaye A; Rochwerg B
Blood Adv; 2018 Nov; 2(22):3317-3359. PubMed ID: 30482767
[TBL] [Abstract][Full Text] [Related]
20. Real-life treatment of venous thromboembolism with direct oral anticoagulants: The influence of recommended dosing and regimens.
Trujillo-Santos J; Di Micco P; Dentali F; Douketis J; Díaz-Peromingo JA; Núñez MJ; Cañas I; Mastroiacovo D; Saraiva de Sousa M; Monreal M;
Thromb Haemost; 2017 Jan; 117(2):382-389. PubMed ID: 27786333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
